clinical trial · NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb·phase2·recruiting·n = 234
Advanced Renal Cell Carcinoma (RCC)PumitamigIpilimumabCabozantinibNivolumab
brief summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
started
Mar 26, 2026
primary completion
Nov 28, 2029
completion
Nov 26, 2031
last updated
May 13, 2026
official title
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol